Growth hormone and the heart

Clinical Endocrinology

Volumn 54, Issue 2, 2001, Pages 137-154

  Colao, Annamaria ^a   Marzullo, Paolo ^a   Di Somma, Carolina ^a   Lombardi, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACROMEGALY; BONE GROWTH; CARDIOVASCULAR FUNCTION; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; GROWTH REGULATION; HEART DEVELOPMENT; HEART MUSCLE CELL; HEART PERFORMANCE; HUMAN; LIFE EXPECTANCY; METABOLIC ACTIVATION; PRIORITY JOURNAL; REVIEW; SUBSTITUTION THERAPY;

ACROMEGALY; ADULT; ANIMALS; CASE-CONTROL STUDIES; CHILD; FEMALE; GROWTH HORMONE; HEART; HEART DISEASES; HEMODYNAMIC PROCESSES; HORMONES; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; OLIGOPEPTIDES; RATS; STROKE VOLUME;

EID: 0035115172     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2001.01218.x     Document Type: Review

References (191)

1. Cabergoline in the treatment of acromegaly: A study in 64 patients
2. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses
3. Myocyte cell loss and myocyte hypertrophy in the aging rat heart
4. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adul onset before and during human GH treatment
5. Cardiac effects of lanreotide, a slow release somatostatin analog, in acromegalic patients
6. Progression of cardiovascular disease in acromegalic patients treated by external pituitary irradiation
7. An audit of outcome of treatment in acromegaly
8. The effect of hypopituitary on life expectancy
9. An overview of cardiac function and implication for growth hormone: Cardiomyopathy
10. Cardiovascular disease and risk factors in adults with hypopituitarism
11. Cardiovascular effects of prolonged growth hormone replacement in adults
12. The restoration of cardiac hypertrophy and blood pressure in hypophysectomized rats by large doses of lyophilized anterior pituitary and growth hormone
13. Cardiac effects of hexarelin in hypopituitary adults
14. Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans
15. Radionuclide angiocardiographic evaluation of the cardiovascular effects of recombinant human IGF-I in normal adults
16. Idenfication and characterization of a new growth hormone-releasing peptide receptor in the heart
17. Nitric oxide mediates the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency
18. Impaired left ventricular diastolic filling in patients with coronary artery disease: Assessment with radionuclide angiography
19. Asynchronous left ventricular regional function and impaired global diastolic filling in patients with coronary artery disease: Reversal after coronary angioplasty
20. Effects of aging on asynchronous left ventricular regional function and global ventricular filling in normal human subjects
21. Decrease in carotid intima-media thickness after 1 year growth hormone (GH) treatment in adults with GH deficiency
22. Increased common carotid intima-media thickness. Adaptative response of a reflection of atherosclerosis? Findings form the Rotterdam study
23. On the actions of the growth hormone-releasing hexapeptide, GHRP-6
24. Patients with dilated cardiomyopathy show reduction of the somatotroph responsiveness to GHRH both alone and combined with arginine
25. Activity of GH/IGF-I axis in patients with dilated cardiomyopathy
26. Increased cerebrovascular mortality in patients with hypopituitarism
27. Cardiovascular and renal effects of growth hormone
28. Increased arterial intima-media thickness in childhood-onset growth hormone deficiency
29. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide
30. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: A review
31. Growth hormone secretagogues: Physiological role and clinical utility
32. Decreased regional blood flow in patients with acromegaly
33. Heart failure responsive to octreotide in patient with acromegaly
34. Cardiovascular effects of the somatostatin analog octreotide in acromegaly
35. Growth hormone replacement therapy in adults with growth hormone deficiency improves vascular reactivity
36. Impaired cardiac performance in GH-deficient adults and its improvement after GH replacement
37. Insulin-like growth factor-1 but not growth hormone augments mammalian myocardial contractility by sensitizing the myofilament to Ca2+ through a wortmannin-sensitive pathway: Studies in rat and ferret isolated muscles
38. Differential cardiac effects of growth hormone and insulin-like growth factor-I in the rat. A combined in vivo and in vitro evaluation
39. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy
40. Growth hormone deficiency in elderly patients with hypothalamo-pituitary tumors
41. Impaired cardiac performance in elderly patients with growth hormone deficiency
42. Does the age of onset of growth hormone deficiency affect cardiac performance? A radionuclide angiography study
43. Impact of patient's age and disease duration on cardiac performance in acromegaly: A radionuclide angiography study
44. Effects of one-year treatment with octreotide on cardiac performance in patients with acromegaly
45. Effects of octreotide pretreatment on surgical outcome in acromegaly
46. Effect of different dopaminergic agents in the treatment of acromegaly
47. Growth hormone and prolactin excess
48. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR® in acromegaly
49. Extensive personal experience: Acromegaly
50. Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly
51. Recombinant human insulin-like growth factor-1 increases forearm blood flow
52. The heart in acromegaly
53. Cabergoline in acromegaly: A renewed role for dopamine agonist treatment?
54. Cardiac failure responding to growth hormone
55. Improved left ventricular function after growth hormone replacement in patients with hypopituitarism: Assessment with radionuclide angiography
56. Impaired left ventricular diastolic filling in patients with acromegaly: Assessment with radionuclide angiography
57. Clinical aspects of growth hormone deficiency in adults
58. Cardiac ischemia and impairment of vascular endothelium function in hearts from growth hormone deficient rats. Protection by hexarelin
59. Localization of the insulin-like growth factor system in a rat model of heart failure induced by myocardial infarction
60. Insulin-like growth factor I and its binding proteins in the cardiovascular system
61. Regulation of insulin-like growth factor 1 messenger RNA levels in vascular smooth muscle cells
62. Cardiovascular and metabolic effects of insulin-like growth factor-I at rest and during exercise in humans
63. Induction of myocardial insulin-like growth factor-I gene expression in left ventricular hypertrophy
64. Cardiovascular effects of insulin-like growth factor 1 and growth hormone in chronic left ventricular failure in the rat
65. Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure
66. Cardiovascular function and glucocorticoid replacement in patients with hypopituitarism
67. Insulin-like growth factors and neonatal cardiomyocyte development: Ventricular gene expression and membrane receptor variations in normotensive and hypertensive rats
68. Cardiovascular mortality among pituitary insufficient patients
69. Endothelial dysfunction in hypopituitary adults with growth hormone deficiency
70. Long-term growth hormone deficiency as a cause of cardiomyopathy and its reversibility with specific replacement therapy
71. Cardiovascular effects of short-term growth hormone hypersecretion
72. Impaired cardiac performance is a distinct feature of uncomplicated acromegaly
73. Evidence for biventricular involvement in acromegaly: A Doppler echocardiographic study
74. A preliminary study of growth hormone in the treatment of heart failure in patients with dilated cardiomyopathy
75. Pharmacotherapy or surgery as primary treatment for acromegaly?
76. Inhibitory effect of octreotide on growth hormone-induced IGF-I generation and organ growth in hypophysectomized rats
77. The effect of insulin-like growth factor-1 on adult rat cardiac contractility
78. Cell death in acromegalic cardiomyopathy
79. Growth hormone in the treatment of dilated cardiomyopathy
80. Reversible dilated cardiomyopathy due to growth hormone deficiency
81. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients
82. Octreotide long-acting release (LAR). A review of its phamacological properties and therapeutic use in the management of acromegaly
83. Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide
84. Impaired spontaneous growth hormone secretion in severe dilated cardiomyopathy
85. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor
86. Insulin like growth factor-1 increases glomerular filtration rate and renal plasma flow in man
87. Effect of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects
88. Cardiac insulin-like growth factor I and growth hormone receptor expression in renal hypertension
89. Cellular localization of somatomedin (insulin-like growth factor) messenger RNA in the human fetus
90. Induction of cardiac insulin-like growth factor-I gene expression in pressure overload hypertrophy
91. Potential new cardiovascular risk factors: Left ventricular hypertrophy, homocysteine, lipoprotein (a), triglycerides, oxidative stress, and fibrinogen
92. Lung function in acromegaly
93. Acromegalic heart disease: Influence of treatment of the acromegaly on the heart
94. Acromegaly and the heart: A clinical and pathologic study
95. Evidence that insulin-like growth factor-I increases renal plasma flow and glomerular filtration rate in fasted rats
96. Effects of insulin like growth factor-1 on renal function in normal men
97. Effects of growth hormone and insulin on amino acid transport in perfused rat heart
98. A receptor in pituitary and hypothalamus that functions in growth hormone release
99. Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostafin analog)
100. Anatomie pathologique, lesions et trouble cardiovasculaires de l'acromegalie
101. Signalling pathways for cardiac hypertrophy and failure
102. Body water and sodium in patients with acromegaly
103. A placebo-controlled study of growth hormone in patients with congestive heart failure
104. Growth hormone regulates the level of insulin-like growth factor-I mRNA in rats skeletal muscle
105. The role of the GH/IGF-I axis for cardiac function and structure
106. Increased expression of growth hormone receptor mRNA and insulin-like growth factor-I mRNA in volume overloaded hearts
107. Serum total IGF-I, free IGF-I and IGFBP-1 levels in elderly population. Relation to cardiovascular risk factors and disease
108. Beneficial effects of growth hormone and insulin-like growth factor-1 in experimental heart failure in rats treated with chronic ACE inhibition
109. Long-term cardiovascular effects of growth hormone treatment in GH-deficient adults. Preliminary data in a small group of patients
110. Arrhythmia profile in acromegaly
111. Insulin reduces contraction and intracellular calcium concentration in vascular smooth muscle
112. Coordinate expression of the insulin-like growth factor system after microembolisation in porcine heart
113. Control of cardiac gene expression by mechanical stress
114. Octreotide
115. Results of a European multicentre study with sandostatin LAR in acromegalic patients
116. Elevated fibrinogen levels decrease following treatment of acromegaly
117. Molecular and cellular aspects of the insulin-like growth factor I receptor
118. Aortic distensibility in growth hormone deficient adults
119. Pathology of the heart in acromegaly: Anatomic findings in 27 autopsied patients
120. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion
121. Growth hormone-independent cardioprotective effects of hexarelin in the rat
122. Left ventricular function in young adults with childhood and adulthood onset growth hormone deficiency
123. Cardiac involvement in acromegaly: Specific myocardiopathy or consequence of systemic hypertension
124. Bromocriptine for an acromegalic patient. Improvement in cardiac function and carpal tunnel syndrome
125. Growth hormone as a risk for premature mortality in healthy subjects: Data from the Paris prospective study
126. Detection of premature atherosclerosis by high resolution ultrasonography in symptom-free hypopituitary adults
127. Cardiac effect of thyrotoxicosis in acromegaly
128. Acromegaly and cardiovascular disorders: A prospective study
129. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly
130. Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency
131. Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalics
132. Elastic properties of the myocardium: A quantitative approach with physiological and clinical applications
133. Blockade of the renin-angiotensinaldosterone system prevents growth hormone-induced fluid retention in humans
134. Cardiac hypertrophy and function in asymptomatic acromegaly
135. Acromegaly
136. Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac and pulmonary function in patients with hGH deficiency acquired in adulthood
137. Treatment of end-stage cardiac failure with growth hormone
138. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults
139. Heart valve operation in acromegaly
140. Mortality and cancer incidence in acromegaly: A retrospective cohort study
141. The severity of chronic heart failure due to coronary artery disease predicts the endocrine effects of short-term growth hormone administration
142. Randomised, double-blind placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy
143. Acromegalic cardiopathy improves after treatment with increasing doses of octreotide
144. Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults
145. Determinants of clinical outcome and survival in acromegaly
146. Upregulation of IGF-I, IGF-I receptor and late growth-related genes in ventricular myocytes after infarction in rats
147. Subclinical cardiac dysfunction in acromegaly evidence for a specific disease of heart muscle
148. Premature cardiovascular mortality in hypopituitarism-a study of 333 consecutive patients
149. Protectant activity of hexarelin or growth hormone against post-ischemic ventricular dysfunction in hearts from aged rats
150. Cardiac physiology, biochemistry and morphology in response to excess growth hormone in the rat
151. Insulin-like growth factor-I gene expression is increased in the right ventricle hypertrophy induced by chronic hypoxia in the rat
152. A comparison of the effect of IGF-I and insulin on glucose metabolism, fat metabolism and the cardiovascular system in normal human volunteers
153. Growth hormone and the heart
154. Echocardiographic assessment of cardiac anatomy and function in patients
155. Patterns of myocardial gene expression after cycles of brief coronary occlusion and reperfusion
156. Morphologic study of microcirculation in acromegaly by capillaroscopy
157. Myocardial dysfunction in treated adult hypopituitarism: A possible explanation for increased cardiovascular mortality
158. Acromegalic cardiopathy: A left ventricular scintigraphic study
159. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice
160. Acromegaly and the heart. An echocardiographic study
161. Hyperinsulinemia, insulin resistance, and hyperglycemia: Contributing factors in the pathogenesis of hypertension and atherosclerosis
162. Evaluation of growth hormone administration in patients with chronic heart failure secondary to coronary artery disease
163. Exogenously administered growth hormone and insulin-like growth factor-1 alter intracellular Ca2+ handling and enhance cardiac performance. In vitro evaluation in the isolated isovolumic buffer-perfused rat heart
164. Electrocardiogram in endocrine and metabolic disorders
165. Intense sympathetic nerve activity in adults with hypopituitarism and untreated growth hormone deficiency
166. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly
167. Long-term effects of growth hormone (GH) replacement in men with childhood-onset GH deficiency
168. A hyperkinetic heart in uncomplicated active acromegaly. Explanation of hypertension in acromegalic patients?
169. The cardiovascular effects of octreotide treatment in acromegaly: An echocardiographic study
170. Short and long-term cardiovascular effects of growth hormone therapy in growth hormone deficient adults
171. Effects of chronic growth hormone hypersecretion on intrinsic contractility, energetics, isomyosin pattern and myosin-adenosin thriphosphatase activity of rat left ventricle
172. The growth hormone secmtagogue hexamlin improves cardiac function in rats after experimental myocardial infarction
173. Effects of octreotide on left ventricular mass in acromegaly
174. Body composition in growth hormone deficient adult over the age of 60 years
175. Elderly patients with adult-onset growth hormone deficiency are not osteopenic
176. Beyond the somatopause: Growth hormone deficiency in adults over the age of 60 years
177. Insulin like growth factor I receptors in human cardiac myocytes and their relation to myocardial hypertrophy
178. Direct demonstration of insulin-like growth factor I induced nitric oxide production by endothelial cells
179. Growth hormone in the treatment of dilated cardiomyopathy
180. Cardiac performance and mass in adult with hypopituitarism: Effects of one year of growth hormone treatment
181. Growth hormone therapy in adults and children
182. Insulin-like growth factors and insulin increase the contractility of neonatal rat cardiocytes in vitro
183. Hemodynamic effects of intravenous growth hormone in congestive heart failure
184. Left ventricular insulin-like growth factor-I increases in early renal hypertension
185. Insulin-like growth factor-I diminishes in vivo and in vitro vascular contractility: Role of vascular nitric oxide
186. Effects of IGF-I gene deletion on postnatal growth patterns
187. Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: Relation to growth hormone levels and insulin-like growth factor I
188. Mortality in acromegaly
189. Endothelial-dependent vascular effects of insulin and insulin-like growth factor I in the perfused rat mesenteric artery and aortic ring
190. Decreased transient outward K+ current in ventricular myocytes from acromegalic rats
191. Growth hormone improves cardiac performance in experimental heart failure